Creative Pharma Technologies Profile
Key Indicators
- Authorised Capital ₹ 6.00 M
as on 15-11-2024
- Paid Up Capital ₹ 5.10 M
as on 15-11-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 Cr
as on 15-11-2024
- Revenue 11.51%
(FY 2023)
- Profit 48.39%
(FY 2023)
- Ebitda 429.93%
(FY 2023)
- Net Worth 341.16%
(FY 2023)
- Total Assets 79.29%
(FY 2023)
About Creative Pharma Technologies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 M and a paid-up capital of Rs 5.10 M.
The company currently has active open charges totaling ₹5.00 Cr.
Pawan Solanki, Sumatiprakash Jain, and Mayank Jain serve as directors at the Company.
- CIN/LLPIN
U74999MH2017PTC292293
- Company No.
292293
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Mar 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Creative Pharma Technologies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pawan Solanki  | Additional Director | 15-Jul-2024 | Current |
| Sumatiprakash Jain | Director | 10-Mar-2017 | Current |
| Mayank Jain | Director | 10-Mar-2017 | Current |
Financial Performance and Corporate Structure Insights of Creative Pharma Technologies.
Creative Pharma Technologies Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.51% increase. The company also saw a substantial improvement in profitability, with a 48.39% increase in profit. The company's net worth Soared by an impressive increase of 341.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Creative Pharma Technologies?
In 2023, Creative Pharma Technologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Viilbery Healthcare Private LimitedActive 16 years 5 monthsSumatiprakash Jain and Mayank Jain are mutual person
Westova Mining And Merchandising Private LimitedActive 1 year 21 daysPawan Solanki is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Nov 2022 | ₹5.00 Cr | Open |
How Many Employees Work at Creative Pharma Technologies?
Unlock and access historical data on people associated with Creative Pharma Technologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Creative Pharma Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Creative Pharma Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
